Digg StumbleUpon LinkedIn YouTube Flickr Facebook Twitter RSS Reset
Comments Off

GASTROINTESTINAL AND LIVER DISEASE – Exercise 35

By | Published: November 3, 2015

The multiple choice questions in this online test paper focuses on GASTROINTESTINAL AND LIVER DISEASE MCQ. If you are looking for self evaluation of your PG Medical entrance exam preparation then this online GASTROINTESTINAL AND LIVER DISEASE MCQ Test Paper will help you to evaluate your exam preparation.

Instruction for REPRODUCTIVE BIOLOGY/ REPRODUCTIVE MEDICINE / INFERTILITY MCQs:

1- This online MCQ practice test paper contains 30 questions.
2- Each question in this online practice test paper have four options and only 1 option is correct.
3- You can view the answers of this practice test paper after submitting the practice test paper.
Note: The answers mentioned at the end of practice test are the best suitable option as per our knowledge. Users shall cross-check the answers with their textbooks.

Q 1. most common symptom in chronic hepatitis C

 
 
 
 

Q 2. antibody seen in chronic hepatitis D

 
 
 
 

Q 3. patients with which HBV genotype has highest rate of IFN induced HBeAg loss

 
 
 
 

Q 4. nonreplicative phase of chronic HBV infection is characterized by all except

 
 
 
 

Q 5. first approved treatment of chronic HBV infection

 
 
 
 

Q 6. replicative phase of chronic HBV infection is characterized by

 
 
 
 

Q 7. following drug is beneficial in severe acute hepatitis B

 
 
 
 

Q 8. antibody prevalent in patients with chronic HCV infection

 
 
 
 

Q 9. following side effects of IFN α therapy is irreversible on cessation of therapy

 
 
 
 

Q 10. which factor is the most important in progression of liver disease in chronic hepatitis C

 
 
 
 

Q 11. for HBeAg reactive chronic HBV infection antiviral therapy is indicated for patients with

 
 
 
 

Q 12. in CHB, factor that is not predictive of a response to antiviral therapy is

 
 
 
 

Q 13. PEG stands for

 
 
 
 

Q 14. recommended regimen of peg IFNa-2a for CHB is

 
 
 
 

Q 15. following antiviral drugs has dual antiviral activity against HBV & HIV

 
 
 
 

Q 16. nephrotoxicity of adefovir is best related to

 
 
 
 

Q 17. following is approved for treatment of chronic HBV infection

 
 
 
 

Q 18. which of the following differentiates natural immunity by resolved HBV infection from that which is acquired through vaccination

 
 
 
 

Q 19. in patients with HBV-HIV infection which should never be used as monotherapy

 
 
 
 

Q 20. most important risk factor for development of cirrhosis & HCC in chronic HBV infection is

 
 
 
 

Q 21. inhibitory dose of lamivudine for treating HBV/HIV coinfected patients is

 
 
 
 

Q 22. extrahepatic complications unrelated to immune complex injury in chronic hepatitis C are all except

 
 
 
 

Q 23. for HBeAg negative chronic HBV infection antiviral therapy is indicated for patients with

 
 
 
 

Q 24. therapy with which of the following least likely to result in emergence of viral mutations

 
 
 
 

Q 25. best prognostic indicator in chronic hepatitis C is

 
 
 
 

Q 26. serum HBV DNA undetectable by PCR is defined as

 
 
 
 

Q 27. interferon α therapy is not effective in which of the following groups of CHB patients

 
 
 
 

Q 28. not a complication of chronic hepatitis B

 
 
 
 

Q 29. most potent of the HBV antivirals is

 
 
 
 

Q 30. HBV inactive carriers is characterized by all except

 
 
 
 


pgmedmin

Comments are closed.